PanDox: Targeted Doxorubicin in Pancreatic Tumours
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study will combine focused ultrasound to generate heat, and a heat-sensitive
chemotherapy drug (ThermoDox®), delivered into the blood of participants with non-resectable
pancreatic cancer. We will compare this to standard delivery of chemotherapy - the drug
Doxorubicin given into the blood without the addition of ultrasound. We aim to determine
whether the novel approach to delivering chemotherapy with heating the tumour by focused
ultrasound can enhance the amount of drug delivered to pancreatic tumours. This will be
measured by analysing a biopsy sample of treated tumour.
Phase:
Phase 1
Details
Lead Sponsor:
University of Oxford
Collaborators:
Celsion National Institute for Health Research, United Kingdom Oncology Clinical Trials Office